Pyoderma gangrenosum study pilot registry: The first step to a better understanding

• Published in: Wound repair and regeneration 2022-05, Vol.30 (3), p.334-337
• Main Authors: Orfaly, Victoria E., Reese, Ashley M., Friedman, Marcia, Latour, Emile, Ortega‐Loayza, Alex G.
• Format: Article
• Language: English
• Subjects: chronic wounds; clinical research; Humans; Pilot Projects; Prospective Studies; Pyoderma Gangrenosum - diagnosis; Pyoderma Gangrenosum - drug therapy; Registries; wound care; Wound Healing
• ISSN: 1067-1927; 1524-475X
• DOI: 10.1111/wrr.13005

The objective of this study was to develop a pilot physician driven patient pyoderma gangrenosum (PG) registry to summarise patient baseline demographics, PG‐related medical history, treatments, and outcomes for patients with pyoderma gangrenosum. Standardised patient information was collected prospectively during clinical encounters between December 2019 and July 2021 at a single academic institution. Eligibility criteria for the study was a diagnosis of pyoderma gangrenosum determined by a PARACELSUS score of at least 10 for ulcerative patients. Main outcome measures included demographic data, PG related history and comorbidities, past and current treatments, healing outcomes, hospitalisations and recurrences of PG. The Pyoderma Gangrenosum Study (PYGAS) Registry currently includes 52 patients with 56 target lesions of four distinct PG subtypes (41 ulcerative, 12 peristomal, 2 vegetative and 1 bullous). For the 38 patients with 41 total ulcerative PG lesions, referrals to our institution most commonly came from dermatologists (42.1%). The median follow‐up time in our initial registry was 5.5 months (95% CI = 4.1–11.5 months), with average time between follow‐up visits at 1.1 months. These ulcers were most commonly treated with first‐line systemic immunosuppressants (70.6%), such as corticosteroids or cyclosporine. Additional use of systemic immunomodulators at baseline visit was statistically significantly associated with healing (P = 0.048). This pilot study suggests that use of systemic immunomodulators has an impact on healing of PG patients. Wound care regimens are variable, and assessing their impact on treatment outcomes could be challenging. Standardisation of both wound care regimens and data collection in prospective clinical studies is necessary to assess their impact in PG treatment outcomes.